ArticleJournal of pharmacy & bioallied sciences2025
Evaluation of the 6-Month Effect of Sacubitril-Valsartan Compared to ACEI and ARB on LVEF in Heart Failure Patients: A Double-Blind Randomized Clinical Trial.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Heart failure is a common condition that affects millions of people worldwide. The aim of this study was to evaluate the 6-month effect of sacubitril-valsartan (SV) compared to angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) on left ventricular ejection fraction (LVEF) in heart failure patients. Methods: This is a clinical trial involving heart failure patients (n = 225) referred to Farshchian Heart Hospital in Hamadan-Iran from April to September 2023. The patients were randomly assigned to three groups receiving SV (n = 75), ACEI (n = 75), and ARB (n = 75). In all three treatment groups, LVEF was checked and compared by echocardiography before the treatment and 6 months after the treatment. Results: The mean scores of an increase in EF compared to before treatment in the SV, ACEI, and ARB groups were 1.73 ± 2.78%, 0.69 ± 1.93%, and 0.14 ± 1.42%, respectively ( Conclusion: In this study, SV was shown to be superior to ACEI and ARB in improving LVEF in heart failure patients at 6 months follow-up. These findings highlight the potential benefits of SV in the management of heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.